Bepirovirsen
Highest phase reached
Phase 3
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Oligonucleotide
- Drug name
- Bepirovirsen
- bepirovirsen
- Bepirovirsen
- bepirovirsen [INN]
- BEPIROVIRSEN [USAN]
- Bepirovirsen [WHO-DD]
- bepirovirsen inn
- bepirovirsen usan
- bepirovirsen who dd
- dna d p thio 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl m5rc 2 o 2 methoxyethyl ra 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl ra g g t g a a g m5c g a 2 o 2 methoxyethyl ra 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl m5ru 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl m5rc
- DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-G-G-T-G-A-A-G-M5C-G-A-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC)
- gsk 3228836
- gsk 3228836b
- GSK-3228836
- GSK-3228836B
- gsk3228836
- Gsk3228836
- GSK3228836
- gsk3228836b
- GSK3228836B
- ionis hbvrx
- IONIS HBVRX
- isis 505358
- ISIS 505358
- isis gsk3rx
- ISIS-505358
And 1 more, listed on the interactive page.
- CAS registry numbers
- 1403787-62-1
- ChEMBL ID
- CHEMBL4650468
- FDA ingredient codes (UNII)
- Z87O6SM01N
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- bepirovirsen
- Type
- Nucleic acid
- Drug name stem
- -rsen; -vir-
- Approval recorded by Guide to Pharmacology
- Yes
- Mechanism
- mRNA antisense inhibitor
- Action type
- ANTISENSE_INHIBITOR
- Target
- mRNA
- Mechanism
- mRNA antisense inhibitor
- Action type
- Inhibitor
- Target
- mRNA
- Condition
- Hepatitis B
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004197
- Subject identifier
- D006509
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004197
- Subject identifier
- D019694
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition identifier
- EFO_0004197
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004239
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005366
- Highest recorded phase
- 2
- NCT04449029
- NCT04544956
- NCT04676724
- NCT04954859
- NCT04971928
- NCT05330455
- NCT06058390
- NCT06422767
- NCT05276297
- NCT05630807
- NCT05630820
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (17)
- A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
- A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
- A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
- A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants
- A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
- A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants
- Bepirovirsen Liver Biopsy Study
- Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
- Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
- Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
- Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
- Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
In development for (3)
- Chronic hepatitis B virus infection Phase 3
- Hepatitis B virus infection Phase 3
- HIV infectious disease Phase 2